The traditional bulk API market is on the rise after the boom

Xu Ming, vice president of the China Pharmaceutical and Health Products Import and Export Chamber of Commerce in, said that since last year, the traditional bulk raw materials trade has shown no signs of warming up and will be in the downward channel for a long time to comeChina's traditional bulk API exports prematurely into the growth bottleneck, but the new growth point has not yet been fully formed, the export situation is grimV6U
After the prosperity of the traditional bulk API market
V6Uin fact, exports into the bottleneck of growth is only one side of China's bulk API declineWith the tightening of domestic environmental protection policies, clinical restrictions on the use of antibiotics, the traditional bulk apiening domestic demand is also declining, internal and external problems are testing the production of raw materialsFor these enterprises, has reached the critical moment when we must reflect, adjust the industrial structure and enterprise strategyV6U
In January last year, The H-share "China Pharmaceuticals" of The H-shares of The Company, a company of Ishiguro Group, changed its name to "Stone Pharmaceutical Group" and injected innovative drugs and research and development of high-quality businessThe Chinese newspaper of The Stone Pharmaceutical Group showed that, benefiting from innovative drugs, the overall performance increased significantly, the enterprise product structure has been from the past API and formulation ratio of 3:5 to the current 5:5, the enterprise transformation is basically completedIndustry insiders said that Ishiguro Group is the leading domestic API production enterprises, but also the rapid pace of transformation of one of the enterprisesDue to years of high investment in research and development, some of their preparation products have a better market acceptance, but the pain of corporate transformation will continueV6U
　　As we all know, China's API enterprises to listed companies mainly, its predecessor is mostly state-owned enterprises Shen Xianji, chairman of the expert committee of the China Chemical and Pharmaceutical Industry Association, said that API is the basis for pharmaceutical development China's pharmaceutical industry started late, backward technology, in a long time the state to encourage the development of raw materials to meet the needs of ordinary people State-owned enterprises in this period under the guidance of policy to become the first to benefit from the main body, not only expanded the scale, increased efficiency, but also laid the leading position of the industry All along, China's development of the traditional bulk apinics to penicillin series, vitamin series and anti-hot analgesic-based With the transfer of global API industry in the 1990s, China has gradually become the traditional bulk API production center Xu Ming, vice president of the China Medical and Health Products Import and Export Chamber of Commerce, V6U, said that since last year, the traditional bulk raw materials trade has shown no signs of recovery and will be in the downward channel for a long time to come China's traditional bulk API exports prematurely into the growth bottleneck, but the new growth point has not yet been fully formed, the export situation is grim V6U
　　After the prosperity of the traditional bulk API market
V6U in fact, exports into the bottleneck of growth is only one side of China's bulk API decline With the tightening of domestic environmental protection policies, clinical restrictions on the use of antibiotics, the traditional bulk apiening domestic demand is also declining, internal and external problems are testing the production of raw materials For these enterprises, has reached the critical moment when we must reflect, adjust the industrial structure and enterprise strategy V6U
　　In January last year, The H-share "China Pharmaceuticals" of The H-shares of The Company, a company of Ishiguro Group, changed its name to "Stone Pharmaceutical Group" and injected innovative drugs and research and development of high-quality business The Chinese newspaper of The Stone Pharmaceutical Group showed that, benefiting from innovative drugs, the overall performance increased significantly, the enterprise product structure has been from the past API and formulation ratio of 3:5 to the current 5:5, the enterprise transformation is basically completed Industry insiders said that Ishiguro Group is the leading domestic API production enterprises, but also the rapid pace of transformation of one of the enterprises Due to years of high investment in research and development, some of their preparation products have a better market acceptance, but the pain of corporate transformation will continue V6U
　　As we all know, China's API enterprises to listed companies mainly, its predecessor is mostly state-owned enterprises Shen Xianji, chairman of the expert committee of the China Chemical and Pharmaceutical Industry Association, said that API is the basis for pharmaceutical development China's pharmaceutical industry started late, backward technology, in a long time the state to encourage the development of raw materials to meet the needs of ordinary people State-owned enterprises in this period under the guidance of policy to become the first to benefit from the main body, not only expanded the scale, increased efficiency, but also laid the leading position of the industry All along, China's development of the traditional bulk apinics to penicillin series, vitamin series and anti-hot analgesic-based With the transfer of global API industry in the 1990s, China has gradually become the traditional bulk API production center V6U